Soleno Therapeutics, Inc. (SLNO) P/E Ratio History
Historical price-to-earnings valuation from 2025 to 2025
Loading P/E history...
SLNO Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Soleno Therapeutics, Inc. (SLNO) trades at a price-to-earnings ratio of 135.8x, with a stock price of $52.95 and trailing twelve-month earnings per share of $0.38.
The current P/E is 34% below its 5-year average of 204.2x. Over the past five years, SLNO's P/E has ranged from a low of 204.2x to a high of 204.2x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, SLNO trades at a 508% premium to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, SLNO commands a significant premium over the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our SLNO DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
SLNO P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 9.9 | -Best | +68% | |
| $5B | 8.3Lowest | -Best | +264%Best | |
| $9B | 43.4 | -Best | +128% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
SLNO Historical P/E Data (2025–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $46.30 | $0.23 | 204.2x | +0% |
Average P/E for displayed period: 204.2x
See SLNO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SLNO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SLNO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSLNO — Frequently Asked Questions
Quick answers to the most common questions about buying SLNO stock.
Is SLNO stock overvalued or undervalued?
SLNO trades at 135.8x P/E, below its 5-year average of 204.2x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does SLNO's valuation compare to peers?
Soleno Therapeutics, Inc. P/E of 135.8x compares to sector median of 22.3x. The premium reflects expected growth above peers.
What is SLNO's PEG ratio?
SLNO PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2025-2025.